# Microsoft and Novo Nordisk describe AI agent for clinical-trial analysis

- Published: 2026-11-11T21:40:16.000Z
- Updated: 2026-11-12T10:03:39.019Z
- Section: Development
- Topics: Agents, Research
- Page: https://aidailyjournal.com/en/n/2026/11/11/microsoft-and-novo-nordisk-describe-ai-agent-for-clinical-trial-analysis/
- Sources: [Microsoft](https://commandline.microsoft.com/from-custom-infrastructure-to-hosted-agents)

## Summary

Microsoft described an agent developed with Novo Nordisk for secondary analysis of clinical-trial data. The system interprets questions, inspects data, writes and executes code, examines the results, and may revise its approach before returning a summary and visualization. According to Microsoft, the solution was reimplemented as a hosted agent in Microsoft Foundry after an initial version ran in Azure Container Apps, with PostgreSQL and dynamic sessions for isolated code execution.

In Foundry, the platform manages the endpoint, agent identity, state persistence, scaling, and session lifecycle. Each session receives a VM-isolated environment, with compute provisioned on demand. Sid Prabhu of Novo Nordisk said the change enabled the company to deliver a reliable and secure experience to thousands of researchers faster, without building and operating all the infrastructure itself.

## Why it matters (editorial interpretation)

The case illustrates how an agent can turn questions about clinical trials into reproducible analyses by combining interpretation, code, and visualizations. According to Novo Nordisk, hosting it in Foundry reduced the need to build and operate all the infrastructure, helping the company deliver what it described as a reliable and secure experience to thousands of researchers faster.

_Summary written by AI Daily Journal in its own words, based on the sources above. For details, read the original articles._